Physician profile
Patrick D Stowell
NPI 1720022239
$6,648.52
in general payments reported to CMS, 2019-2025
38 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,762 · 2020: $270 · 2021: $29.08 · 2022: $979 · 2023: $1,504 · 2024: $1,007 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,608.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,028.56 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $931.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $744.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $525.77 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.99 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $487.52 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $333.54 | 2019-2025 | Evenity, Repatha, Prolia |
| Glaxosmithkline, LLC. | $279.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $203.27 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.59 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $164.35 | 2019-2020 | Xyosted |
| Merck Sharp & Dohme LLC | $162.45 | 2019-2025 | Verquvo, Capvaxive, M-M-R II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.40 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $118.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $99.22 | 2019-2023 | Spravato |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Stowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.